Abstract：【Objective】To investigate the protective effects of Ulinastatin combined with continuous blood purification on myocardial injury in patients with severe sepsis. 【Method】The 160 cases of severe sepsis patients with myocardial injury were randomly divided into four groups. The C group (control group), U group (Ulinastatin group), CBP group (continuous blood purification group), and A group (Ulinastatin combined with continuous blood purification group). Tumor necrosis factor α(TNFα), interleukin6 (IL6), superoxide dismutase (SOD), malondialdehyde (MDA), arterial blood lactate (LAC), creatine kinase MB(CKMB), lactate dehydrogenase (LDH), troponin I (cTnI), brain natriuretic peptide (BNP), and APACHE Ⅱ scores were measured before treatment and five days after treatment. Cardiac complications of 5 days to 28 days after treatment and the prognosis after 28 days were all recorded. 【Results】All scores showed no significant difference before treatment (P＞0.05). Compared with group C after treatment, LAC and MDA of Group U, and SOD of Group CBP had no significant change (P＞0.05). INFα, LAC, MDA, IL6, CKMB, LDH, BNP, cTnI, and APACHE Ⅱ scores in group A were significantly decreased (P＜0.01） but SOD in group A was significantly higher (P＜0.01）. Compared with Group C, heart failure in Group U, and myocardial infarction in Group CBP were not significantly different (P＞0.05). Heart failure, myocardial infarction, and 28d mortality rates in Group A were significantly decreased (P＜0.01）.【Conclusion】 Ulinastatin combined with continuous blood purification can significantly reduce myocardial injury in patients with severe sepsis and improve both the prognosis of patients and production rate of deposit.
2016, Vol. 33 
